$17.07
6.82% today
Nasdaq, Apr 03, 06:47 pm CET
ISIN
US45783C1018
Symbol
TIL
Sector
Industry

Instil Bio Inc Stock price

$18.32
+0.04 0.22% 1M
-39.68 68.41% 6M
-0.77 4.03% YTD
+7.82 74.48% 1Y
-201.68 91.67% 3Y
-381.68 95.42% 5Y
-381.68 95.42% 10Y
Nasdaq, Closing price Wed, Apr 02 2025
+1.30 7.64%
ISIN
US45783C1018
Symbol
TIL
Sector
Industry

Key metrics

Market capitalization $119.55m
Enterprise Value $91.29m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 0.71
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-56.05m
Free Cash Flow (TTM) Free Cash Flow $-55.70m
Cash position $115.15m
EPS (TTM) EPS $-11.39
P/E forward negative
Short interest 14.51%
Show more

Is Instil Bio Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Instil Bio Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a Instil Bio Inc forecast:

3x Buy
75%
1x Hold
25%

Analyst Opinions

4 Analysts have issued a Instil Bio Inc forecast:

Buy
75%
Hold
25%

Financial data from Instil Bio Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs 3.63 3.63
25% 25%
-
-3.63 -3.63
25% 25%
-
- Selling and Administrative Expenses 37 37
2% 2%
-
- Research and Development Expense 12 12
70% 70%
-
-52 -52
36% 36%
-
- Depreciation and Amortization 3.63 3.63
25% 25%
-
EBIT (Operating Income) EBIT -56 -56
36% 36%
-
Net Profit -74 -74
53% 53%
-

In millions USD.

Don't miss a Thing! We will send you all news about Instil Bio Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Instil Bio Inc Stock News

Neutral
GlobeNewsWire
about one month ago
Clinical data for AXN-2510/IMM2510 monotherapy in relapsed/refractory NSCLC in China by ImmuneOnco, as well as additional safety data in other solid tumors, anticipated in 1H 2025
Neutral
GlobeNewsWire
3 months ago
ImmuneOnco announced dosing of first patient in its recently initiated Phase 1b/2 clinical trial of IMM2510/SYN-2510 in combination with chemotherapy in patients with advanced NSCLC in China
Positive
Seeking Alpha
4 months ago
Instil Bio is a clinical-stage biotech focusing on personalized immunotherapy. SYN-2510 targets the promising PD-L1/VEGF oncology pathway. The company recently licensed assets from ImmuneOnco Biopharmaceuticals, retaining commercialization rights outside Greater China and enhancing its global market positioning. SYN-2510 is advancing to Phase 2 trials for NSCLC and TNBC, addressing a TAM foreca...

Company Profile

Instil Bio, Inc. is a clinical-stage biopharmaceutical company engages in developing cell therapy pipeline of autologous tumor infiltrating lymphocyte therapies for the treatment of patients with cancer. The company was founded in August 2018 and is headquartered in Dallas, TX.

Head office United States
CEO Bronson Crouch
Employees 14
Founded 2018
Website www.instilbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today